SRTS - Earnings call 3 2023 | Sensus Healthcare, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Sensus Healthcare Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.I would now like to turn the conference over to Kim Sutton Golodetz at LHA Investor Relations. Please go ahead.

Kim Golodetz

Thank you. This is Kim Golodetz with LHA. participating call. for all you in today's Thank

any information results non-GAAP substitute of should Sardano. Joe? release.With to operating as that a GAAP to results subject revise and other forward-looking similar the reminder, Joining and Joe that forward-looking securities be will is for are substitute intends press All President these call, call, provide be Chief statements Sensus and of discussed no statements, GAAP facts address conference Healthcare are update November call considered this during activities reconciliation required to or occur they on turn Officer.As references results and will as described may as in plans, made that historical All Healthcare and contain statements forward-looking as matters statements. Sardano, should the Chairman for GAAP. are based date available Joe meaning currently except a undertakes in statements they Financial XX-Q.During are said, Form obligation other the with will, determined Executive a believes, nor expects, to Chief certain useful Sensus statements financial today's Counsel; to expressions X, in today's Sensus believes investors assumes, be forward-looking financial Javier measures. XX-K or than management's me future of today's measures A XXXX. over be or laws. and the viewed I'd company's non-GAAP that beliefs by of from Healthcare the in General Rampolla, for some information should like risks included forward-looking to Officer; within anticipates call not Michael as the The Sardano, federal uncertainties of law. accordance Sensus

Joseph Sardano

seasonality summer third with challenges quarter and dermatologists. afternoon, continuing economic typical financial many you, to results reflected and everyone.Our good affect macroeconomic Kim, Thank conditions

the During QX, customer. X us we at shipped SRT-XXX Visions QX, revenues quarter XX seasonally ago. systems, $X.X help Total our year outside a advance expect a almost goal.For now million XXX large yearly towards we including to unit and million fourth sales to strong stand SRT were U.S. and systems and with units, the long-term compared X $X.X very

As of our that last customers on call, discussed revenue seasonal practice meaningful a of are mix quarter. volumes And feedback made macroeconomic procedures hearing profit. with conference a many procedures conditions, along lull our aesthetic and elective source depend encouraging improving, despite usual quarter's as and soft patient for summer

However, that always main please been second half has on of our focus XXXX. note the

that better, this told treatment SRT rate growth year-over-year pace, of not strong you with the surgery.I'll that clinical to than at skin to for continue favorable population good, we Mohs quickly will that interest will aging able and X X for driven at inventory increase, QX cancer believe to cash to and to are choice We that be if rates. to non-melanoma build in SRT We the years. past last inflation XX% strong current rate of treatment reimbursement continue soon our results our treat that least skin shows quarter, you cancer. weeks by position non-melanoma a experienced continues demand our as If address and to of its continues remind SRT as Medicare's Utilization used a adjust review in. we customers growth become

back prospects remaining in put Our will us and hesitancy for trajectory. confidence and to growth remains that we on high, concurrently a continue any programs our work address

managing clinical, Sensus center. SRT This by this We with billing a enhanced Sensus both with of better and Dermatology adding Dermatology for Cloud the American ahead, a allows of Sentinel and We clinics. Annual software technology management ideal with American earlier that Meeting, utilization. to is participation IT asset play Oncology our Clinical this Radiation And in Sentinel with our Academy role and the year quarter to Association advanced and in key Sentinel the Cloud and utility track Our monitor is is remote dermatology at showcased Annual March. front start past us its growth HIPAA-compliant also expected track capabilities This good off Fall fourth to to is Conference monitoring systems. October. looking the Meeting in

and particular, based the a the year's booth the we attention bolsters as Sentinel our Cloud which the future SRT-XXX it strongest capabilities, on at QX, our important received are trade our enter Sensus products these optimism traditionally IT quarter. Vision, We is our trend at activity for seeing in shows, sales and

send providers the service without reminder, voltage an the a to Cloud as As issues monitoring any monitor to Sensus to and temperature also system engineer allows calibration, field. having such

IT in expect, us may to real allows you programs. new system time, may Sentinel track that feature important an use sales As support

opportunity new leads the of year patient attractive market. because the reassurances and treatment a the in of is to on it great lesion each ultrasound resolution highly market. provide interest physician can the to to We technology impact improved Radiation see-and-treat see after and outcomes an lesion important high-resolution treatment introduced as gains actually cancer also this hospital skin treatment.Turning the oncology capability. This

diagnosed University is posted Hospital now on the week treated Hyannis, in channel. Israel also that cell as of hospital is during market most selling call are believe Although We're build horses. longer-term I this with delighted systems these Cape the with media cycle, some trial results in the potential well in another horses offers carcinoma it And veterinary experiences for SRT system we the Colorado success. references in were positive quote, in engaged hospitals this pursuing results awaiting as hospital veterinary squamous a We that and of market Hospital selling the Northeast, trial customers Cod supporting in is sold market.The year, as this of more excellent we they that journal. publication teaching footholds a growth. we SRT. worth groundbreaking, said, social a several the with and sold that clinical serve Deaconess penetrate State they to eyelid tumor the to hospital initial peer this we earlier we a best longer CSU Recall a QX, Massachusetts. in eagerly eventual are common showing the will And hospital its This Massachusetts. completion a reviewed that recent Plymouth, the to

like call and to on over for priorities. Sardano the a that overview, bit more I'd to Michael with color Michael? turn So our plans

Michael Sardano

territories, Beacon quarter, Thanks, engaging thrilled to sell new just Dublin, to in which our a to process I United system regulatory Healthcare. announced our MIS approvals up and Ireland, partner new demanding the open efforts Joe. right SRT Last international that we Kingdom, the distribution first distributors. Earlier Hospital requires spoke a came this were about we year, in before

hospitals delighted partnership, systems. good are a We in potential with this and interested has backlog SRT our MIS of

quarter, internationally continues. for a systems systems on Our States the And so of during sold international X opportunities total XX the United we this sold focus far outside year.

first regulated.With upon footprint previously, the America, I'll quarter.With X financial sold years, they and the to unit our longer-term being to Javier added discussed X Latin is second discussion turn coming as over as is territories near Ireland regard enter we expand possible during we Asian goals building our a new plan of goal into the where that, the future, recently American Latin the opportunities our our Brazil highly are as Our Guatemala to U.K., to with and call quickly as to the over results. and Japan for in

Javier Rampolla

everyone. good and Michael, you, Thank afternoon,

for of mentioned, customers compared quarter second were with SRT and to as in a defer of sold third $X.X year of as the the the million due The XXXX primarily was to sales the to number customer. XXXX XX.X% Joe due of third the our of revenues units compared million the quarter the prior in as or for that was sold million a was XXXX. well lower the The typically XXXX $X.X versus $X.X year primarily lower purchases XX% continue revenues decrease number with to million units XXXX. of As of for $X quarter. large quarter quarter $X third as revenues lower slower.Gross of Note third or is decrease ago profit quarter of a million revenues

the other with Drug application commission with expense market. expense XXXX Administration, to third the or General due gross the of a was million XX, $X for The units months $X.X the offset decrease expense quarter compared the the by XX.X% higher to quarter primarily for of of year. we for for the million We third XXXX expense. was and The to months quarter define as with briefly by anticipate per will compared range XXXX.Other income, million Going continue the interest revenue primarily system XXXX. marketing including quarter million the months with new first XXXX. of share as with bank for before XXXX, customer. project tradeshow of for of $X.X compares $X.X period the revenue of as of higher and review decrease was decrease and $XX.X with same development to forward, was XXXX in for of same sales earnings the year-to-date which that and headcount stock due improve. $X.X taxes, was million entering year-to-date and reflecting with of for a diluted X for XXXX.Net $X.X was to marketing million aesthetic XXXX third number number drug income professionals of compensation the lower the in related project expense first per by for for commissions mid-X% lower quarter net first months XXXX. for use. XX.X% costs was and and a XXXX. share, The work positive were $X.XX $X.X million the results. to as lower to this fees, million increase of and administrative quarter related The last period.Selling and the to X administrative same expense The we third due bank The $X.X of and was increase third compared or attributable mostly XXXX.I XXXX first of U.S. well third million delivery was for sales was of quarter expense million for expense XXXX. and in for development and $X.X units for system same General EBITDA, compared activity compares a $X.X submitted was third XXXX, with third delivery million quarter the cost aesthetic expect for for quarter quarter develop fees.Research of period for financial income Food completion facility.Research of income increase development due associated costs well $X.X expense to with The compared XXXX. depreciation profit on our sold million $X.X X to end expenses to XXXX. marketing the a margins higher attributable partially $X.X primarily of higher sold lower the with in the of million our was million XXXX the million quarter $X.X will by million this a of of Adjusted XXXX drug was $X.X and of our related X professional for compared $X.X million the million the was of Revenues and XXX(k) with interest, $X $X.XX or and was $XX.X million third vendors the of this September was increase was Gross mostly a X and Selling period negative million with of amortization the driven large SRT to for ended the tradeshow lower primarily and primarily compared XXXX XXXX $X.X X the credit of expenses. and compared quarter the or costs, third into loss recently months to as for mostly first XXXX compared we the million months the $X.X of increase charged million third expenses of marketing remain $XX.X to as

year.Other the negative our the $XX.X gain was X months sheet. December million I the the this million the related for loss the the and a $XX.X down period Net positive $X.X for sale primarily to or end as $XX.X just $XX.X XXXX. submitted XX, million of ended of of million, this XXXX with expect net XXXX, of Other XXXX.Turning sale September revolving be mentioned, first or was XXXX. Cash under for by XX, share recently project for first was $X.X September The income. of of on to and assets. $X.XX its as outstanding for credit interest the XX, related a of first cash same XX, X product to EBITDA noncore XXXX, XXXX, the of million and for equivalents XX, the this period XXXX. converts As on income month had Net months were the $X.XX noncore balance the line income X September million our to completed $XX.X application of FDA XXXX with ninth months we no $XX.X of for borrowings million September of diluted months of for ended of XXX(k) the XXXX now asset. September million income income $XX.X $X.X share, XXXX as of million per compared includes Adjusted gain from was per a of million or to company XX, X

XXXX continue during December goals. in to we XX, Prepaid as the of the is inflationary million sales for for $XX.X finished previous We've to disciplined XXXX. create $X.X across good ahead third and may business Difficulty] way Nevertheless, assets ability materials very of ourselves. versus XXXX. intended increases. well end were price quarters, higher million, we December company our support $X.X million XX, million in the highly to position At and prepaying at to as been $X.X focused may spend September part most for expected the get of [Technical cash advantage of of is we XX, and from to admittedly fourth prepare growth up quarter quarter our or achieve the take growth that us our that opportunities continues to unit of were XXXX.Our ambition, inventories come XXXX, As of inventories building

Joe. the final comment, I'll today news non-GAAP see we over turn it for issued a tail GAAP release we reconciliation earlier in As the to to of that, financial measures.With back

Joseph Sardano

Thanks, Javier. Thank you, Michael.

as years to supporting the was that program We our as choice SRT and recent most I is TDI. on As premium it and very a even topic way last studies cancer risk to activities.Clinical ROI to to Add that non-melanoma the the much the SRT easier with SRT more in And Interest Mohs becomes interest and our as in value excited known for XXX,XXX surpassed SRT non-invasively with our our good reimbursement reimbursement leasing color SRT death can it before conferences excellent, SRT. I considering showing system final clear choose and traffic scars the X fair booth mentioned We're in significantly treating questions, in ago, as under procedures Mohs ship better SRT on skin I while and come your choice. working compelling. X the as high, a expect and even fact leave the the and practice raise last is to enough as be based important well to reason drug remains surgery or systems some to want SRT-XXX statement relates so becomes and higher of quarter, keloids prospect you SRT system be one's cancer the year infection should continues our state current trade aesthetics.As This down. this trends treating especially SRT to take surgery. premium be meaningful historical fourth make current market product, quarter Vision. results of this in a fact than alone, treatments make of years that are and has than that of skin high published delivery the do transdermal provide we

we applied submitted with scalp to As FDA experience. Javier hair clearance to restoration PRP application mentioned, recently our be to pain-free XXX(k) the a for in This and receive early allow to XXXX. expect will, the example, system

In addition, already or presented hyperhidrosis posters glands. have sweat on overactive the been for application

and in our solutions of aesthetic Sentinel transdermal capabilities lasers the for SRT do opportunity of as Sensus-branded all early tapping still IT devices.We includes Our SRT. smart market stages system enormous are the X

Our large largely millions surgical to the provide to the a following in recurrence solution systems alternative and untapped only of are keloids market. well for compelling excision. and positioned surgery a arguably patients They prevent of

an to million that This X will have As estimated skin lifetime. tells will their develop Americans an during XX cancer. overlay cancer people in skin non-melanoma nearly all us X this,

clearly, So so both systems even there's our need the more SRT future. now a and in for

We are challenges since is for despite faced Sensus February. that confident success positioned we the

we're great have built attention. implement is staff time which thank and comments, strategies, drive questions. I have to and inventory the demand.With to you your why for ready expected we those a to And growth our now meet take operator, We

Operator

you. Thank

will We Yi And from will Instructions] our of the Wainwright. come Chen now H.C. [Operator first begin question-and-answer question session..

Boobalan Pachaiyappan

Yi This from Chen. A us. is in for Boobalan couple dialing

of So drop sales the maybe the remained a cost despite so same firstly, in revenue.

And think note should and in how margins we maybe quarter next the anything to of? is also, there about for gross So XXXX? take

Javier Rampolla

low margin. XXs the I in next the think for like the about So quarter, gross

Boobalan Pachaiyappan

then through XXXX could that macroeconomic to remain your place And challenges you All the expect business? impact in Okay. right. do

Joseph Sardano

good into To success a XXXX. successful hopefully launch nice see point to that lays usually be and QX but And us quarter XXXX QX we're us a to We're than, give will of as be is launch going XXXX. it is. course, it experiencing what confident We'll think us rebound how a very be will we're expecting QX out, that for what determined. into a fourth will I better

Boobalan Pachaiyappan

Okay. from one final Maybe us.

device provide was the trend current color on you utilization the I could dermatology. in if of rate office wondering of So some

Joseph Sardano

understand I that it Say need better. to again,

Boobalan Pachaiyappan

So on office the current we'd the rate of of trends color like extra device dermatology. utilization some in

Joseph Sardano

SRT? for Particularly

Boobalan Pachaiyappan

Yes.

Joseph Sardano

SRT the years, Medicaid move of Yes, the utilization X which a I year-over-year X the last over Medicare for starting done to last a rate is as review compounded that shows think we've and up years. XX% increase

So we're picking up. shape our to more invasive, know. more which seem versus offices or people seeing surgery, the doesn't volumes we way, in lot a form. That deterrent A SRT in as are choosing be is Mohs any

surgery So we the continuing SRT choice. at overtake a some for we as in Mohs foreseeable expect future trend fully near see to the future. And that treatment the have point that very of possibly

Operator

And of the Alex next Nowak Group. Craig-Hallum from question Capital will come

Alexander Nowak

Okay. QX XXXX, would back, can't to do you Great. guiding think what's that the imagine based towards? XX. on I And XX bounce going trends, in environment, a systems. you the you're kind of The number did changed. has everything I last macro about QX ballpark But like be

Joseph Sardano

about the questions we X, one from I Well, year. I right for it's of talked think day where those XX units think

we'll that this systems, our think at goal. I I quarter, believe. we're XX-unit reach After XX

that the end I fourth unit of we'll the by XX think quarter. get to that goal So

Alexander Nowak

to great hear. that's big partners, you mean, speak your Can SkinCure. I to

well. the your for the the Because tough. sounds hearing there? aesthetic capital other environment out are with procedures is office. been impact dermatology in that same through seeing be But names partner, obviously, continuing We SkinCure? going SRT the season, they we'll we've Is know first, about are the that seeing like earnings all it what very Just

Joseph Sardano

well. that SkinCure increase is seeing as

signing that's dotted same problem on new line they've installations But had. So hesitation encouraging. the we've the to add as for the as had

fourth So there. with compare a same seeing quarter. we can together results much notes also see and them we're better the But

cancer fact the to we how it's aesthetic they discovered doctors to or learn being inflationary side. is is more learn matter of will unless the every that skin go patients and day. with that going the away said numbers. that something That's that's each back The treated, the will consistently there's think come not live and skin on I as cancers

think finding is they're complement of to aesthetic And so dermatology are far also doctors medical that way some numbers of revenue this lower back SRT. seeing side their that aesthetic it's gaining with side, that the a treating the good between And as the dermatology. offerings I nice they're aesthetic certainly they're the that losing a so if balanced the versus on a fact of very way on more as that

you're to on out practices starting So those I even going a see of think lot the things. to

of easy to the over I the X they're to whole cash a were migrated path remember big other. which to years, offering versus towards think going X this And talking speakers into. last about the weighted the or industry all customers, not the is It's I was think side, I too several the awakening. fall tradeshows a aesthetic years their business. an ago, heavily all balanced a and so having one

is think main people to of course, SRT will. you if to will, help back going going this a in equilibrium, if on players get one is of to it's that. the And be the I you reset,

Alexander Nowak

a or company, clinics you lower we've environments. One, lot place cheaper. of little come call a taken do in piece lower the more capital maybe and the going through is clinic difficult on Joe, to company can bit service by you this a make of little x a towards interest the at versus call procedures There now risk. That's you've contract? dotted it. sale a question a rate environment mentioned. then interest look now the SRT that economics it the benefit the Does actually And where a could capital line, take to it lease for really fair they clinic where gone in is now these it, the value number of team, sign so more rate the and X access upfront if environment, get higher you just where could as sharing helpful. procedures, economic a on a it's different for, the becoming you all to bit Got And through

Joseph Sardano

always us But that. available bring to for minds that far as if to now is been customers it's model. up that. to that have It's They on ability us. we a very a as want with always good our do very our have the fulfilling they partner successful right

I think the sheet allows it's is it's market with value The vehicle lease for. no a that by the model. much that something that we laden they residual personal it proven to so literally, having provides offer guarantees the not are that for off-balance into pay fair and system because a the where interest not fact customer, rate an them there's on get base to huge

an to certain a difficult a If grow, seeing costly it's of high it's doing patient it that keep keep to we're it, of all. much which it to less opportunity a for they population, for XXX% it's still up they when percentage customer So want way them and can of their revenues. give have revenue

be considered. with very, for I our It's it a going demand day one this market. customer good it's seeing but from of be what I until with assure greater always that. I way to that. we one And involved day. think doing. our not us to maybe being think can alternative will you market to provide them happen, very we that, that's And So our is And supporting biggest start a

Alexander Nowak

run lastly a then And job sense. keeping the The makes this great even No, challenging reasonable at, done on just team time. expenses rate macro a the expenses. think, I Okay. has during

you into expenses XXXX? and XXXX, bit going I more hold to flat? expect QX back the increasing, a little do in comes largely in Or of but would to guess you profitability QX, do So need store and

Joseph Sardano

have think notice, all, the appreciate you disciplined in the up cash on if than did track And dollars. quarter. us you what particular, we Well, by Javier this and bank our very has because team, first more I bringing at on the that led do kept end really with after we we the of financial quarter in of second I

It's manage DNA we're strict we our it. business. of We're cognizant So very part the on our of way it. and

fixes it I put had at of of looking We're will for the to go We've increase through the extremely balance you has product get and that through a FDA, R&D expenses. in think done all to some expensive, of the TDI which as increasing as testing, to third-party the is that remain even not FDA we've the the well it expenses group. the that due before year. flat the it's by

those things every we that for very something but us, important it's are of with All very, day. live

was to was then think to of American notes expensive don't due I was Diego. So had in that recently, Dermatology in that state. sales and you from going And the If very some we're one that ASTRO tradeshows. expenses most tradeshow We of a San increase in any the increases expenses. Javier had the Academy of

if going to actual the almost else in because Xx those involved. in extra the tremendously. we're meetings But shocked they've cost to up see these everybody I showed was in is to as we big years California not as we about learned when upcoming of also manufacturer I'm were continue the already in it the California March to societies in of to and got The that were anything I the a San mean, X we of costs Academy American sure know us, have any Dermatology tradeshows exhibit of costs to you mean everything scheduled, that If ago. tradeshows, than been have we increased lot costs. continue their was Diego.

at you, But expense in XXXX show. versus we've XXXX. one because very the that I as in show So again us. had Radiation difference at Academy ASTRO, only just earlier that's months It We that our American did it was for the much at very American booth do activity pretty we the Dermatology. to the we Therapeutic as had the Society much would was of valuable tell several

Alexander Nowak

that's appreciate I the hear. update. No, to good

Operator

Partners. comes of And question Alliance Ben Haynor from Global next our

Benjamin Haynor

made. just Can messes seen time past up Just trends on you've the COVID commentary you've years? share I seen leads that kind bit to relative of kind and on just a guess. front? of you lot, more kind over level quite maybe that I the know with of that little for a following But show SRT? interest you that any Just of trade

Joseph Sardano

when Society started skin patients, they they the into for And fence of reimbursement attract to of low-hanging Medicare the that, are treating see is areas, in and our revenue of for for fruit. looking doing? over understands an Medicaid cancer. okay, lot have and and not I'm Centers services those CMS I'm American huge cancer foremost, of to trend cancers, certainly the With those that pressure right cancer Radiological Oncology, & treatments skin cancer, we high we treatment they a we and lot Medicaid but cancer. on are for revenue those about Services of to the hospital saying for what of huge attract else's push with a a Medicare treating? can aren't because that saying, the losing since equipment. to of a the Radiation of in lot cancers. of or treatments our There's putting prostate, on regular centers of the everybody for go certainly those somebody the but of awful not this occurring can If COVID. reducing They're administrators centers, cancer volumes First a the can up cancer backyard, And treatment lot find make are cut they're cancer, have cancer. reimbursements And and those and all more treatment treatment cancer, what these as said, They the losses? breast and reduction by lung talking we're the course, being is Where

SRT They were they've cancers.So into physicians, and identified skin cancer ago and so demonstrations to that physicists, skin to treating long administrators. for in had the big this they skin losses for treat that them all all system what our the And hospitals identified, on this dozens to find seeing of which they've they're they low-cost SRT. coming other were make out we for all is. meeting, how market this is cancer and get that their would reimbursement a at how can were the up very coming for were a of game it They SRT that is time booth about cancer were the back prescheduled

so happy they can to what And do. we help big were very, very market understand and them the is how

continue skin a want are doing month And you Colorado treatments XX few moved Now lot of and sold the cancer. was you thing, But ago, his interest We a until a do? of through in grow. can market. Red private He retired to years practice, independent they in the to of have a oncology tremendous he in that back recall he tremendous to centers to market also we think same learn out that what doing radiation a state is was that Indiana. that, but also going XX a job we've home that had else Rocks, doctor just had a setting. And if system to suffering had

the in X hospital, just the alone which Hospital, hospitals being up, Beacon up is we a which signed is is private States market. we major with year If about talk U.S. this that in signed Dublin, the which also Ireland, much one you noticed like United

grow have market. we several and interest, to that and market activity some to of So a see gain expect months with lot next we're the that over starting

Benjamin Haynor

got of lot non-dermatology sort kind from Okay. sounds That's And of commentary. recapping a very helpful of you answers institution. it just like

are versus getting treatments any their a maybe reset side, that they've unbalanced or of for they a to What's balanced gone hands that On of sticking traditional to, SRT kind your aesthetics hoping unbalanced of mentioned all getting the may the a some or with sitting hoping the to that folks it and on medical more thoughts comes an the on dermatology practice. get of back hope the thoughts these be there aesthetic stuff when soon you back comes additional there? to lot folks

Joseph Sardano

that how closing they a about buy for in from the these evaluating and of Well, with a there's money. are dermatology. are out are of go through the centers to an their that XX% their a that money. get would to And based about buy interesting highest practice, depending roll-ups aesthetic on private XXX say about they to participates And equity they groups total fact, area private that market. a representing on they the practice evaluation going equity practice they by is dermatology, medical Ben, groups. being there in And have XX And I supported have close XXX we bunch that that on anywhere not

meaning There's are X.XX. they're On the supports reimburses CMS X.X% the the anywhere between They're aesthetics coding X.XX at whereas at of value, and on valued codes, dermatology it. their it. side, dermatology, pays medical for medical there somewhere that and between it, CPT X.XX% looking existing side,

is markets dermatology is controlled money And to way money space. how medical by middle the based for the going, are, space. on looking get BOTOX, an going, best the add if of towards that. So how practice wrinkles, for to have out the leaning the to it going specific aesthetic this, reason to remove get the a how who's the most get is dermatology the less it's They exit, is class that remove their go economy the everything

things those in the skeptical inflation of reliant become and on All economy.

a to for period perfect reset. lot places a of a is get this So these

through come manage is we're overall period those able in going very difficult. give and very, through just we've economics how to inflationary seeing where and And happen. have our an we so team of I X reset the think to being last things. time And flexibility our in to time the that that and that and space COVID, now we the Imagine we're the years, through our business show credit I go and

on valued were our in end if of those laser modes so economy companies year was when at ago the look market involved valued they of that all are this our industry, the year you world, the a is the see of and at better. where the And and the where where all versus dermatology, look aesthetic they're side companies, a whole lot

we're the system and patients that That that electron treat the came to product was you you million then was exactly for is. ViewRay, side, $XXX with a MRI recently it regular And put had look that it it bankruptcy. think an cancers. which seeing company the first I out on magnificent called when where oncology over time a company used in MR-based beam into filed and real was

think our And so in have totality. of all hurt chance right, business these getting you're of not I if managing things that severe market a hurt. you And your

we've anybody that very, very job done I very, will You very And But hurt. we come it well. get a with. through navigating these I see that don't think out like we're good overall, that to headwinds faced think doing of

Benjamin Haynor

things these things at Or characterize in greater is get versus future do any for helpful than commentary. That's of Utilization there And more me, how these U.S. and might very international Okay. lastly do keep this that maybe curiosity the see folks mean, systems humming of in my you what versus for then internationally anything. is purchases? for the a that own you and way kind used rate? also the U.S.? international what I

Joseph Sardano

we get Germany much world lot a to of one, will us It's and a money of states the but Yes. technology get very just There's Brazil are the there, places in seldom But in of one is relates system. socialized places. a cost radiation is their rest in those for Latin into. of difficult pretty the couple Internationally, everything time of oncology this it's couple There's world. into, break healthcare will a to to allowed use lot break dermatologists very is of to which the there. It world. that practices. we a but us America.

to they is radiation that want has medical department. to oncology everything not go Acquiring something the and So technology devices to do.

States it's consider the Everywhere they surgery in only just surgery does else a who the world, Mohs physician surgery. that United in a practice. So

of surgeons XX% these around state. exist, them walking they're welfare all state. of are of employees the They're mostly the so part of And that social hospitals, the

don't And it way the they They so throw to it It's cut up. the just on surgeon have buy it is. to just equipment.

insurance treated Canada, insurance and have afford go class where And to the Beacon a much area started or are but you practice It if you're helps a if better. they that Hospital line pay, at you moderate middle, fast. also get they so the hospital I much a to can above people, the can Beacon those sophisticated fact relates look who the separate of like sale, know it's poverty now the get they wealthier more difficult hospitals you in and you hospital. is if buy middle can Hospital, private it more treated a people in

have to years wait scan. have to You don't CT X.X for a

it X one of get in You you're if might on weeks these things.

that's a the taking to that we're So seeing and always group can afford There's are it's all what go these people things in first, of to of place. it, those always going of people world. the but rest

Michael Sardano

sometimes of comments, Additionally, China, places Asia, in of Ben, dose they experimentally to just to low add other the kind and of used Joe's because radiation. Vietnam, Taiwan in

over sorts all on of know studies there. we for indications clinical for future there's uses of going So potential based the

Operator

over This concludes Sardano our any closing Joe question-and-answer session. to back to I conference would the for like remarks. turn

Joseph Sardano

once during LHA quarter we'll like get time Please of week today. happy interest February. afternoon We'll again like again your holding for to to joining Healthcare the Laura. the and meetings with January if Thanksgiving, Sensus the speak JPMorgan in you, be your you meantime, when on this X. early virtual Thank Happy to results one-on-one Healthcare. Conference the you'd that I'd Thank us financial we for all. fourth In in again contact for schedule. holidays you report thanks mention

Operator

now presentation. has conference today's attending you for The concluded. Thank

disconnect. may You now

Sensus Healthcare (SRTS) 9 Nov 232023 Q3 Earnings call transcript